Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21264524 | 0.85 | GPR17 (0.46) | GPR17FBP1 | |
| SCHEMBL29617492 | 0.85 | GPR17 (0.46) | GPR17FBP1 | |
| SCHEMBL21264749 | 0.85 | GPR17 (0.46) | GPR17FBP1 | |
| SCHEMBL9191758 | 0.77 | GPR17 (0.69) | GPR17FBP1 | |
| SCHEMBL20094566 | 0.72 | GPR17 (0.60) | GPR17FBP1 | |
| SCHEMBL30559677 | 0.72 | GPR17 (1.00) | GPR17FBP1 | |
| SCHEMBL9192404 | 0.72 | GPR17 (0.71) | GPR17FBP1 | |
| SCHEMBL8463078 | 0.72 | GPR17 (1.00) | GPR17FBP1 | |
| SCHEMBL14739207 | 0.72 | GPR17 (1.00) | GPR17FBP1 | |
| SCHEMBL21264797 | 0.72 | GPR17 (1.00) | GPR17FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339189-B2 | DNA primase and gyrase inhibitors | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-05-24 | — | — | US | disclosed |
| US-20190248836-A1 | DNA PRIMASE AND GYRASE INHIBITORS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2019-08-15 | — | — | US | disclosed |
| WO-2018073828-A1 | DNA PRIMASE AND GYRASE INHIBITORS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248836-A1 | DNA PRIMASE AND GYRASE INHIBITORS | TOP2A, TOP1, DNA2 | GPR17 2448/4885FBP1 901/4885 |
| US-11339189-B2 | DNA primase and gyrase inhibitors | TOP2A, TOP1, DNA2 | GPR17 2448/4885FBP1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.